Search hospitals > North Carolina > Raleigh

UNC Rex Healthcare

Claim this profile
Raleigh, North Carolina 27607
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Peripheral Arterial Disease
Conducts research for Tumors
Conducts research for Peripheral Vascular Disease
76 reported clinical trials
7 medical researchers
Photo of UNC Rex Healthcare in RaleighPhoto of UNC Rex Healthcare in RaleighPhoto of UNC Rex Healthcare in Raleigh

Summary

UNC Rex Healthcare is a medical facility located in Raleigh, North Carolina. This center is recognized for care of Breast Cancer, Cancer, Peripheral Arterial Disease, Tumors, Peripheral Vascular Disease and other specialties. UNC Rex Healthcare is involved with conducting 76 clinical trials across 150 conditions. There are 7 research doctors associated with this hospital, such as Lisa Carey, JoEllen Speca, Ranjit Joseph, and Samantha L Margulies, MD.

Area of expertise

1Breast Cancer
Global Leader
UNC Rex Healthcare has run 16 trials for Breast Cancer. Some of their research focus areas include:
HER2 positive
ER positive
ER negative
2Cancer
Global Leader
UNC Rex Healthcare has run 15 trials for Cancer. Some of their research focus areas include:
ER positive
HER2 positive
PR positive

Top PIs

Clinical Trials running at UNC Rex Healthcare

Breast Cancer
Prostate Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Recurrence
Cancer
Prostate Adenocarcinoma
Tumors
Bone Metastasis
Atrial Fibrillation
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Image of trial facility.

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at UNC Rex Healthcare?
UNC Rex Healthcare is a medical facility located in Raleigh, North Carolina. This center is recognized for care of Breast Cancer, Cancer, Peripheral Arterial Disease, Tumors, Peripheral Vascular Disease and other specialties. UNC Rex Healthcare is involved with conducting 76 clinical trials across 150 conditions. There are 7 research doctors associated with this hospital, such as Lisa Carey, JoEllen Speca, Ranjit Joseph, and Samantha L Margulies, MD.